Kelly Culwell

Kelly Culwell is the Chief Medical Officer for Evofem Biosciences, and an Obstetrician/Gynecologist with over 16 years specializing in women’s health and contraceptive research. Prior to joining Evofem Biosciences, she was a trainer and consultant for Merck and maintained an academic clinical practice as the Director of Family Planning and Associate Clinical Professor at University of California, Davis. She previously served as a Medical Officer with the World Health Organization where she developed global guidelines for clinical practice and is widely published in peer reviewed journals.

Feb14

FROM THE PIPELINE | Evofem Biosciences to advance the MPT market with Amphora®

Thursday, 14 February 2019 Written by // Kelly Culwell Series // From the Pipeline Tags // Amphora, chlamydia, gonorrhea, non-hormonal contraception, women

Evofem Biosciences’ lead product candidate, Amphora® is an MPT – more specifically, a Multipurpose Vaginal pH Regulator (MVP-RTM) – that is being developed for the prevention of pregnancy and certain sexually transmitted infections (STIs), including chlamydia and gonorrhea.

Share

Spread the word about the promise of MPTs.

Collaborate

We will go further together – join the movement for MPTs.

Contribute

Your financial and in-kind support can help make MPTs a reality.